Gyre Therapeutics, Inc.
GYREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Gyre Therapeutics, Inc. (GYRE) is listed under Biotechnology. Valued at $674.5M, GYRE is a small-cap name in its sector. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Market Cap
$674.5M
Beta
4.78
P/E (TTM)
—
P/E (Fwd)
100.83
EPS (TTM)
$-0.08
EPS (Fwd)
$0.06
ROE
-3.1%
ROA
1.0%
Cash
$49.8M
Total Debt
$823,000
Free CF
$9.6M
52W Change
-16.1%
Annual Financials
Cash vs Debt
With $49.8M in cash and $823K in debt, GYRE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $9.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -3.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $102.3M to $116.6M.
With a beta above 1.5, GYRE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Gyre Therapeutics, Inc.'s trajectory.